electroCore to Participate at the Planet MicroCap Showcase

electroCore, Inc. (Nasdaq: ECOR), a leader in bioelectronic medicine, is set to participate in the upcoming Planet MicroCap Showcase at the Paris Hotel & Casino in Las Vegas on April 23 and 24, 2025. This event will feature CEO Dan Goldberger, who will present a group discussion on April 23 at 1:30 PM PT, alongside hosting one-on-one meetings with investors throughout the two-day conference.

As a commercial-stage company, electroCore specializes in non-invasive vagus nerve stimulation (nVNS) technology aimed at enhancing health and well-being. Their focus combines medical device commercialization for treating specific conditions and developing consumer products that leverage nVNS to boost overall wellness and human performance across various markets, including the United States and select international locations.

Investors interested in scheduling a one-on-one meeting with Mr. Goldberger are encouraged to contact Planet MicroCap or reach out to electroCore’s investor relations team via email at ecor@fnkir.com. This engagement at Planet MicroCap provides an excellent opportunity for the company to connect with potential investors and stakeholders, discuss their innovative technologies, and share insights into their current and future business strategies.

To learn more about electroCore, including their revolutionary nVNS technology and its applications, interested parties can visit the company's website at www.electrocore.com. With a commitment to advancing bioelectronic medicine, electroCore is positioned to make significant contributions to the healthcare landscape, leveraging cutting-edge technology to enhance the quality of life for patients and consumers alike.

For investor inquiries, electroCore can be contacted directly at (973) 302-9253 or via email at investors@electrocore.com.

electroCore, Inc. (NASDAQ: ECOR) is gearing up for key visibility at the upcoming Planet MicroCap Showcase, a critical event for small-cap companies looking to attract investor interest. The participation of CEO Dan Goldberger in a group presentation, coupled with the opportunity for one-on-one meetings, indicates an intention to clearly convey the company’s strategy and value proposition to potential investors.

As a bioelectronic medicine company focusing on non-invasive vagus nerve stimulation (nVNS) technology, electroCore presents a unique profile in the biopharmaceutical space. They target both specific medical conditions and broader wellness applications, positioning their products within a growing market for non-invasive treatment alternatives. This dual-focus on both medical and consumer markets enhances the appeal to a diverse investor base.

Analysts should watch closely for updates surrounding electroCore's recent innovations and product pipelines that could significantly influence their revenue potential. Given the increasing interest in bioelectronic medicine, the market is ripe for companies like electroCore that can demonstrate efficacy through clinical trials and obtain necessary regulatory approvals.

Investors should consider the timing of the Showcase; this is an opportunity for electroCore to generate momentum and clarify its growth prospects, especially as they navigate through a landscape that values innovative healthcare solutions. Effective communication during this event could lead to increased investor confidence, potential stock appreciation, and a broader market position.

While the stock may be subject to volatility typical of small-cap biopharmaceutical entities, prudent investors might find value in positioning themselves ahead of significant corporate developments. Attending the Showcase could prove advantageous for obtaining in-depth insights into electroCore’s operational trajectory and strategic objectives. Therefore, monitoring electroCore's post-event updates will be critical for making informed investment decisions.